Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy

Fig. 1

Comparison between r/r MB-NHL and initial remission patients. (a). The mutational spectrum of r/r MB-NHL (n = 48; left) and initial remission patients (n = 28; right). Overview of the top 30 mutated genes with different forms of mutation and their frequencies. Side bar plots indicate the incidence of mutations in a gene in 76 patients. Top bar plots indicate the number of mutated genes per participant. (b). The box plot indicates a comparison of ages between r/r MB-NHL (left, red) and initial remission patients (right, blue). (c). Comparison of mutation profiles between r/r MB-NHL (left, red) and initial remission patients (right, blue). (d). Comparison of the incidence of ARID1A mutations in r/r MB-NHL (left) and initial remission patients (right). Wt, wild-type ARID1A; Mut, ARID1A mutation

Back to article page